You are here: Industry Insights > biologic

News List

Inauguration of the New Richter BioLogics cGMP Facility for the Manufacture of Biopharmaceuticals for the Global Market PharmaSources
October 14, 2024
Richter BioLogics GmbH & Co KG, the microbial biologics affiliate of Gedeon Richter Plc. celebrated the opening of its new cutting-edge biopharmaceutical cGMP facility in Bovenau .
Immunoconjugates: Biological Missiles for Diagnosis and Treatment Suzanne Elvidge
August 02, 2024
Immunoconjugates already play an important role in the treatment of cancer, and their role is likely to expand into other therapeutic indications.
Research Progress on the Application of Biologics in Pediatric Asthma Xiaomichong
July 19, 2024
Asthma is a heterogeneous and complex chronic disease. Children with severe asthma often experience acute exacerbations, ultimately leading to impaired lung function and poor quality of life.
Celonic Inaugurates “Next Generation” Biologics Development Center (BDC) and Pilot Plant in Basel, Switzerland Biotech Newswire
June 24, 2024
The Celonic Group, a Swiss Based Quality Biologics Contract Development and Manufacturing Organization (CDMO) today opened its “Next Generation” Biologics Development Center and Pilot Plant in Basel, Switzerland.
Research Progress on the Application of Biologics in Childhood Asthma. Xiaomichong
October 30, 2023
Asthma is a heterogeneous, complex chronic disease. Children with severe asthma often experience acute exacerbations, leading to impaired lung function and poor quality of life.
Research progress on the biological activity and pharmacological mechanism of naringin Xiaomichong/PharmaSources
September 07, 2023
Naringin is a natural flavonoid compound. It is a colorless needle-shaped crystalline powder that is insoluble in cold water and extremely bitter in taste. Modern pharmacological studies have found that naringin has various therapeutic effects.
Hebei Huaheng Biological Technology well balances policy and price under rising cost of raw material PharmaSources.com
November 17, 2017
Established in 2011 in Jizhou District, Hengshui City, Hebei Province, Hebei Huaheng Biological Technology Co., Ltd. is a hi-tech enterprise based on R&D...
Polpharma Biologics Announces Approval of Europe’s First and Only Biosimilar for Multiple Sclerosis - Tyruko® (Natalizumab) B3C newswire
November 06, 2023
Polpharma Biologics, today announced that the European Commission (EC) has approved Tyruko® (natalizumab) as the first and only biosimilar for relapsing forms of multiple sclerosis (MS) in Europe.
Polpharma Biologics Announces FDA Approval of Tyruko® - First And Only Approved Biosimilar to Tysabri®* for Relapsing Forms of Multiple Sclerosis PharmaSources
August 28, 2023
On August 25, 2023,Polpharma Biologics announced today that the U.S. Food and Drug Administration (FDA) is the first regulatory body worldwide to approve the use of Tyruko®.
Polpharma Biologics Announces First-of-a-Kind Multiple Sclerosis Biosimilar Natalizumab Receives Positive CHMP Opinion PharmaSources
July 24, 2023
Polpharma biologics announces first-of-a-kind multiple sclerosis biosimilar natalizumab receives positive CHMP opinion.